<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004700</url>
  </required_header>
  <id_info>
    <org_study_id>199/13382</org_study_id>
    <secondary_id>CHP-FDR001181-DBPC</secondary_id>
    <nct_id>NCT00004700</nct_id>
  </id_info>
  <brief_title>Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Evaluate the safety and efficacy of long term recombinant human insulin-like growth factor I&#xD;
      in children with hyperinsulinism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, cross-over study.&#xD;
&#xD;
      Patients are randomized to receive recombinant human insulin-like growth factor I (IGF-I) or&#xD;
      placebo subcutaneously twice daily for 4 weeks. After a 2 week washout period, patients are&#xD;
      crossed over to the other regimen for an additional 4 weeks.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1995</start_date>
  <completion_date>January 1999</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>16</enrollment>
  <condition>Hyperinsulinism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin-like growth factor I</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- Diagnosis of hyperinsulinism (i.e., evidence of fasting&#xD;
        hypoglycemia with inadequate suppression of insulin, normal pituitary and adrenal function,&#xD;
        and increased insulin action) Suboptimal control of blood sugar (i.e., inability to fast at&#xD;
        least 10 hours with a blood sugar of 60 mg/dL or greater) --Prior/Concurrent Therapy-- See&#xD;
        Disease Characteristics --Patient Characteristics-- Performance status: Not specified&#xD;
        Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No other&#xD;
        major medical conditions No known adverse reaction to recombinant human insulin-like growth&#xD;
        factor I&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pinchas Cohen</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <verification_date>March 1999</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>endocrine disorders</keyword>
  <keyword>hyperinsulinism</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

